Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens

被引:24
作者
Asahina, Y [1 ]
Izumi, N [1 ]
Uchihara, M [1 ]
Noguchi, O [1 ]
Nishimura, Y [1 ]
Inoue, K [1 ]
Ueda, K [1 ]
Tsuchiya, K [1 ]
Hamano, K [1 ]
Itakura, J [1 ]
Miyake, S [1 ]
机构
[1] Musashino Red Cross Hosp, Div Gastroenterol & Hepatol, Musashino, Tokyo 1808610, Japan
关键词
double-stranded RNA-activated protein kinase (PKR); MxA; viral kinetics; peripheral blood mononuclear cell; real-time detection PCR; interferon-beta;
D O I
10.1016/S0168-8278(03)00287-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: To address the molecular mechanism for enhanced antiviral efficacy associated with a frequent dosing of interferon (IFN)-beta. Methods: Serum hepatitis C viral (HCV) dynamics, double-stranded RNA-activated protein kinase (PKR) mRNA and MxA mRNA levels in peripheral blood mononuclear cells (PBMC) were analyzed serially in 140 patients who were randomly assigned to a twice daily (3 MU bid) or once daily (6 MU qd) administration group. Results: In twice daily group, the rate of HCV decline during the second phase was 2-fold greater than in the once daily group (P = 0.04). Peak PKR and MxA gene expression levels in the first phase (observed 4 h after a single administration) were 2-fold higher in the once daily group. However, the expression in the second phase was maintained at a significantly higher level in the twice daily group. Initial and peak expression levels were related to initial viral load. Basal expressions in PBMC were significantly correlated with those in the liver tissue (PKR, r = 0.81; MxA, r = 0.75, respectively, P < 0.0001). Conclusions: Our data suggest that elimination of HCV-infected cells is enhanced by twice daily dosing of IFN-beta, and that this enhanced effect is associated with a higher intracellular expression of PKR and MxA during the second phase. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:421 / 427
页数:7
相关论文
共 33 条
[1]   Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-α therapy [J].
Antonelli, G ;
Simeoni, E ;
Turriziani, O ;
Tesoro, R ;
Redaelli, A ;
Roffi, L ;
Antonelli, L ;
Pistello, M ;
Dianzani, F .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (03) :243-251
[2]   A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta [J].
Asahina, Y ;
Izumi, N ;
Uchihara, M ;
Noguchi, O ;
Tsuchiya, K ;
Hamano, K ;
Kanazawa, N ;
Itakura, J ;
Miyake, S ;
Sakai, T .
HEPATOLOGY, 2001, 34 (02) :377-384
[3]   In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus [J].
Fernández, M ;
Quiroga, JA ;
Martín, J ;
Herrero, M ;
Pardo, M ;
Horisberger, MA ;
Carreño, V .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :262-267
[4]   Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway [J].
Frese, M ;
Pietschmann, T ;
Moradpour, D ;
Haller, O ;
Bartenschlager, R .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :723-733
[5]   Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase [J].
Gale, M ;
Kwieciszewski, B ;
Dossett, M ;
Nakao, H ;
Katze, MG .
JOURNAL OF VIROLOGY, 1999, 73 (08) :6506-6516
[6]   Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis [J].
Heathcote, EJ ;
Shiffman, ML ;
Cooksley, WGE ;
Dusheiko, GM ;
Lee, SS ;
Balart, L ;
Reindollar, R ;
Reddy, RK ;
Wright, TL ;
Lin, A ;
Hoffman, J ;
De Pamphilis, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1673-1680
[7]   Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-β in patients with genotype 1b hepatitis C infection -: A multicenter randomized study [J].
Izumi, N ;
Kumada, H ;
Hashimoto, N ;
Harada, H ;
Imawari, M ;
Zeniya, M ;
Toda, G .
DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (03) :516-523
[8]  
Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503
[9]  
KOBAYASHI Y, 1993, HEPATOLOGY, V18, P1319, DOI 10.1002/hep.1840180606
[10]  
Lam NP, 1997, HEPATOLOGY, V26, P226